We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DEVICE INDUSTRY FULLY ENGAGED IN U.S.-KOREA FREE TRADE NEGOTIATIONS

DEVICE INDUSTRY FULLY ENGAGED IN U.S.-KOREA FREE TRADE NEGOTIATIONS

July 7, 2006

An initial round of trade negotiations between the U.S. and South Korea in early June has "significant implications" for the device and diagnostics industry, AdvaMed said June 27.

The relationship between the U.S. and South Korea produced nearly $72 billion in trade in 2005. The U.S.-Korea Free Trade Agreement (KORUS FTA) will set precedents for the future, said AdvaMed, which noted that the device and pharmaceutical industries have been a focus of "longstanding trade problems" between the two countries.

South Korea "still maintains tariffs as high as 13 percent," Nancy Travis, AdvaMed's associate vice president for global strategy, said. While that rate is "not terribly high," industry "feels very strongly there should be no tariffs on lifesaving products," she said.

Diagnostic reagents are the No. 1 medical technology export from the U.S. to South Korea, representing a $60 million market in 2005, Travis noted. While the Koreans don't tax those products, they place an 8 percent tariff on catheters, X-rays and ultrasound machines, and polarizing material for eyeglasses, she said.

"If that tariff were reduced to zero, we estimate an immediate savings of $20 million" for U.S. exporters, as well as a savings in treatment costs for Korean patients.

(http://www.fdanews.com/ddl/33_27/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 17Feb

    Effective Auditing for Manufacturing Quality

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • COVID-19

    Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

  • abbott-logo.gif

    Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

  • Fast Tack text

    FDA Gives MeiraGTx’s Achromatopsia Therapy Fast-Track Status

  • Australia_FlagonMap.gif

    TGA Investigates COVID-19 Tests and Emerging Variants

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing